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Methylation of cyclin-dependent kinase inhibitors,
XAF1, JUNB, CDH13 and soluble Wnt inhibitors in
essential thrombocythaemia
C S Chim, T K Fung, R Liang
ABSTRACT
Background Methylation of genes regulating cell-cycle
check-point (INK4 cyclin-dependent kinase inhibitors),
apoptosis (XAF1), adhesion (CDH13), JUNB and Wnt
signalling (soluble Wnt inhibitors) has been implicated in
pathogenesis of haematological and epithelial cancers.
Method The authors studied the methylation status of
CDKN2A, CDKN2B, XAF1, CDH13, JUNB and a panel of
soluble Wnt inhibitors including WIF1, DKK3, APC,
SFRP1, SFRP2, SFRP4 and SFRP5 by methylation-
specific PCR in 31 bone marrow and 21 peripheral blood
samples of patients with essential thrombocythaemia.
Results and discussion There was no evidence of
hypermethylation of all these genes in both the BM and
PB samples. Therefore, in contrast to myeloid
leukaemias, methylation of these genes regulating the
cell cycle, apoptosis, adhesion and Wnt signalling does
not play an important role in the pathogenesis of
myeloproliferative diseases. Whether differential
methylation may occur in the progenitor or mature blood
cell compartments remains to be verified. Our study
contributes to the literature on methylation in chronic
myeloproliferatve diseases.
INTRODUCTION
ET is a stem cell disease with proliferation of the
myeloid compartment, in particular the megakar-
yocytic lineage, leading to thrombocytosis.1 2
About half of the patients carry the JAK2 V617F
mutation with constitutive activation of JAK-STAT
signalling.2 On the other hand, pathogenesis in
those without JAK2 V617F mutation remains
unknown. Moreover, while inactivation of tumour
suppressor genes negatively regulating cell-cycle
progression, apoptosis,3 adhesion and Wnt signal-
ling contributes to carcinogenesis, the role of these
regulators in ET is rarely reported.
Aberrant promoter DNA methylation (gene
hypermethylation) results in gene silencing, and has
been implicated in the pathogenesis of epithelial and
haematopoietic cancers.4 Deregulation of the cell
cycle, apoptosis and Wnt signalling, by virtue of
methylation, and hence silencing, of cyclin-depen-
dent kinase inhibitors, pro-apoptotic factors and
soluble Wnt inhibitors has been reported in a wide
array of haematopoietic cancers.4e7
The cell cycle is tightly regulated at the G1S
check-point by the INK4 and CIP/KIP families of
CKI.3 The Wnt signalling pathway, important in
haematopoiesis, has also been implicated in
leukaemogensis.8 In the canonical Wnt pathway,
binding of Wnt to Frizzled (Wnt receptor) leads to
inhibition of GSK3b, resulting in hypophosphor-
ylation of b-catenin, and hence activation of tran-
scription of target genes.
The canonical Wnt pathway is negatively regu-
lated by a multitude of soluble factors in the
extracellular milieu. These comprise: (1) Wnt
inhibitory factor 1 (WIF1), secreted Frizzled related
proteins (SFRPs) and (3) the Dickkorf (Dkk) family
of secreted proteins. Both WIF1 and SFRP bind to
Wnt ligands and thus inhibit their activities.
Besides, SFRPs may also downregulate Wnt
signalling by the formation of inhibitory complex
with Frizzled receptors. On the other hand, DKKs
acts by depleting Frzzled co-receptors, LRP recep-
tors, from the surface, thereby resulting in failure of
Frizzled activation even in the presence of Wnt
ligands.8 XAF1, which binds to XIAP, is emerging as
an important tumour suppressive pro-apoptotic
factor recently shown to be hypermethylated in
gastric cancer.9 Finally, CDH13 and JUNB, were
frequently hypermethylated in another myelopro-
liferative disease, chronic myeloid leukaemia
(CML).10 11 Moreover, an MPD-like phenotype has
been demonstrated in JUN-B knock-out mice.12
Herein, we studied the role of hypermethylation
of CKIs, XAF1, CDH13, JUNB and a panel of seven
soluble Wnt antagonists including WIF1, DKK3,
APC, SFRP1, SFRP2, SFRP4 and SFRP5 in ET.
Moreover, as mature blood cells in the peripheral
blood are derived from cellular differentiation of the
bone marrow progenitors, we postulated that there
might be a differential methylation pattern in




Sixteen (51.6%) female and 15 male (48.4%)
patients with a median age of 60 years (range:
28e89) were studied. Diagnosis of ETwas based on
the 2001 WHO criteria,13 including a persistent
thrombocytosis of >6003109/l, and exclusion of
reactive causes, MDS, CML (by the absence of
t(9;22)(q34;q11) on conventional karyotyping,
ﬂuorescence in situ hybridisation or BCR/ABL
rearrangement on reverse transcription polymerase
chain reaction, RT-PCR), and other myeloprolifer-
ative diseases (MPD) by a haemoglobin level
<16.8 g/dl with normal marrow iron store and
serum ferritin level, absent or minimal marrow
ﬁbrosis. The study has been approved by the IRB of
Queen Mary Hospital with informed consent.
JAK2V617F mutation, by allele-speciﬁc PCR, was
present in 18 (58.1%) of these ET patients (data not
shown).
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Methylation-specific polymerase chain reaction (MSP)
DNAwas extracted from 31 bone marrow and 21 peripheral blood
samples at diagnosis by the standard method. Of the 21 patients
with peripheral blood (PB) buffy coat DNA, concomitant bone
marrow (BM) samples were available. MSP for aberrant gene
promoter methylation was performed as previously described.5 6
Treatment of DNA with bisulﬁte for conversion of unmethylated
cytosine to uracil (but unaffecting methylated cytosine) was
performed with a commercially available kit (CpGenome DNA
modiﬁcation kit, Chemicon, New York). The methyation status
ofWif1, DKK3, APC, SFRP1, SFRP2, SFRP4 and SFRP5was tested.
Primers for the methylated (M-MSP) and unmethylated (U-MSP)
promoters were previously reported,5 7 and those for XAF1,
CDH13 and JUNB were listed in table 1.9e11 DNA from eight
normal bone marrow donors was used as a negative control, while
methylated control DNA (CpGenome Universal Methylated
DNA, Chemicon) was used as a positive control in all the
experiments. MSP was performed in a thermal cycler (9700, ABI
Biosystems, Foster City, California) with the following cycling
conditions: 958C for 4 min, 35 cycles of 958C for 45 s, speciﬁc
annealing temperature for 30 s, 728C for 30 s and a ﬁnal extension
of 10 min at 728C. The MSP mixture contained 50 ng of bisulﬁte-
treated DNA, 0.2 mM dNTPs, 2 mM MgCl2, 10 pmol of each
primer, 13PCR buffer and 2.5 units of AmpliTaq Gold DNA
Polymerase (ABI Biosystems) in a ﬁnal volume of 50 ml. Ten
microlitres of PCR products was loaded onto 6% non-denaturing
polyacrylamide gels, electrophoresed and visualised under ultra-
violet light after staining with ethidium bromide. SFRP3 was not
studied because of the absence of a CpG island. The study
complied with the Declaration of Helsinski and has been
approved by the Institutional Review Board of Queen Mary
Hospital with informed consent.
RESULTS
The DNA sequence of methylated control DNA for CDH13,
XAF1 and JUNB was aligned and compared with the germline
sequence of the wild-type DNA (WT) (ﬁgure 1). Methylated
cytosine residues in CpG dinucleotide remained as ‘C,’ whereas
unmethylated cytosine were read as ‘T’ after bisulﬁte
conversion. None of the eight normal control marrows showed
aberrant methylation of APC, DKK3, Wif1, SFRP1, SFRP2, SFRP4
and SFRP5 (ﬁgure 1). The positive and negative controls showed
the expected MSP results (normal DNA: U-MSP positive/
M-MSP negative; methylated DNA: U-MSP negative/M-MSP
positive). There was no methylation of CKIs (CDKN2A,
CDKN2B), XAF1, CDH13, JUNB and all the seven soluble Wnt
inhinitors in both the peripheral blood and bone marrow
samples.
DISCUSSION
The essence of gene hypermethylation is that it serves as an
alternative mechanism of gene inactivation. Therefore, it will be
important if gene silencing could be demonstrated in case
a tumour suppressor gene is shown to be hypermethylated.
However, in this study, none of the genes were hyper-
methylated. Moreover, it is unclear if all the marrow cells in
MPD belong to the neoplastic clone, or if there is residual
haematopoiesis. If so, the expression of unmethylated alleles in
the normal haematopoietic cells will confound the expression
study.
There are a few points worthy of discussion. First, while
CDKN2B (alias p15) is frequently methylated in AML including
myelodysplastic syndrome (MDS),6 there is an absence of
methylation of all CKIs in all the ET samples. Despite the fact
that ET is a clonal myeloproliferative disease, in which myeloid
transformations including AML may occur, none of the cases
here showed methylation of the panel of CKIs including
CDKN2B. However, it would be interesting to determine
whether the methylation status of CDKN2A and CDKN2B may
be acquired during leukaemic transformation from an under-
lying MPD.1
Second, in previous studies of the methylation of the same
panel of soluble Wnt inhibitors in other forms of haematologial
malignancies,7 we have shown that multiple Wnt inhibitors
may be hypermethylated in the same sample. Therefore, to
avoid missing methylation in any one of these soluble inhibitors,
the methylation status of the whole panel of seven inhibitors
was studied. Despite this comprehensive approach, none of the
ETsamples displayed methylation of the soluble Wnt inhibitors.
Third, we postulated that the pattern of methylation may be
different in myeloid progenitors and peripheral blood gran-
ulocytes. If so, methylated genes in the myeloid progenitors will
show methylated signal in the bone marrow sample, while
methylated genes in the granulocytes will result in methylated
signals in both the BM and PB compartments. This is particu-
larly relevant, as Wnt signalling is important in haematopoiesis.8
However, none of the samples showed any methylation of any
of these seven soluble Wnt inhibitors, suggesting that methyl-
ation of these soluble Wnt inhibitors is unimportant in the
pathogenesis of ET. Moreover, as none of these Wnt inhibitors is
hypermethylated in either the bone marrow or the peripheral
blood cellular components, the hypothesis of differential meth-
ylation in the progenitor and mature blood cell compartments
could not be veriﬁed.
Finally, the methylation of various tumour suppressors has
been extensively studied in leukaemias and lymphoma but not
myeloproliferative disease. Only recently, there were a few
reports of methylation of the negative regulators of the
Table 1 Methylation-specific polymerase (MSP) chain reaction: primer sequences and reaction conditions
Gene Forward primer (59e39) Reverse primer (59e39) Reference
XAF1 Zou et al9
M-MSP TTTGTAAGAAACGAAATTTAATCGA CCTACCCTTAAAACCCACGAT
U-MSP TTTGTAAGAAATGAAATTTAATTGA CTCCTACCCTTAAAACCCACAAT
CDH13 Roman-Gomez et al10
M-MSP TCGCGGGGTTCGTTTTTCGC GACGTTTTCATTCATACACGCG
U-MSP TTGTGGGGTTGTTTTTTGT AACTTTTCATTCATACACACA






Primer sequences kindly offered by S Baylin.7
M-MSP, MSP chain reaction for the methylated allele; Tm, annealing temperature; U-MSP, MSP chain reaction for the unmethylated allele.
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JAK-STAT signalling pathway, SOCS1 and SOCS3, in various
CMPD regardless of the JAK2 V617F mutation status.13 14 These
reports are interesting, as they conﬁrmed our previous ﬁnding
that SOCS1 exon 2 is hypermethylated, even in normal controls,
and hence is not suitable for methylation study.6 Moreover,
these studies suggest a redundant role of SOCS methylation in
those patients carrying JAK2 V617F mutation, which would
have rendered constitutive activation of JAK/STAT signalling in
the affected myeloid cells, resulting in myeloid proliferation and
hence clinical CMPD.
In conclusion, our study showed that methylation of the
putative tumour suppressor genes negatively regulating the cell
cycle, apoptosis or Wnt signalling is not important in the
pathogenesis of ET. These data contribute to the literature on
methylation in chronic MPDs.
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Take home messages
In contrast to acute leukaemias, genes regulating cell cycle,
apoptosis and Wnt signalling are not hypermethylated in essen-
tial thrombocythaemia. Moreover, although a MPD-like pheno-
type has been demonstrated in JUN-B knock-out mice, JUN-B is
not hypermethylated. Therefore, methylation of other tumour
suppresssor genes should be studied.
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